Stewart Lyman

Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides advice to biotechnology and pharmaceutical companies as well as academic researchers and venture capital firms. Previously, he spent 14 years as a scientist at Immunex prior to its acquisition by Amgen.

Recent posts

Residents of Washington State are currently being buried in an avalanche of ads regarding a citizen’s initiative that would require the labeling of genetically engineered foods sold in grocery stores. Estimates... Read more »

Biopharmaceutical companies are under a great deal of financial pressure these days, and many are tinkering with long established business models. There can be no doubt that the industry is... Read more »

Many fields of endeavor have their own special words, abbreviations, and coded language. People working in each of these disciplines learn over time how to use certain phrases that describe... Read more »

This may seem like a surprising observation, but it’s true. Biopharma companies and baseball teams employ similar strategies that they hope will result in either a blockbuster drug or winning... Read more »

The failure of scientists to independently confirm much of the data contained in “hot” academic publications is casting a long shadow over the biopharmaceutical industry. Research groups at Amgen and Bayer... Read more »

The most successful biotechs of the past quarter century have been companies that established relatively large, cutting edge research programs, such as Biogen, Immunex, and Genentech. I’ll refer to this as... Read more »